SCHEMBL4965715

SCHEMBL4965715

COc1cc2ncnc(N3CCC(NC(=O)Nc4ccc(OC5CCCC5)cc4)C3)c2cc1OC

nearest known ligand 0.60

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
PDGFRA P16234 3/20 0.60
KIT P10721 2/20 0.60
KDR P35968 1/20 0.60
PDE3B Q13370 13/20 0.58
PDE3A Q14432 13/20 0.58
PDE10A Q9Y233 13/20 0.58
PDGFRB P09619 3/20 0.54
PAK1 Q13153 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4974993 0.95 PDGFRA (0.64) PDGFRAKITKDRPDE3BPDE3A
SCHEMBL4968133 0.90 PDE10A (0.56) PDGFRAKITKDRPDE3BPDE3A
SCHEMBL4966365 0.88 PDE10A (0.56) PDGFRAKITKDRPDE3BPDE3A
SCHEMBL4966727 0.87 PDGFRA (0.59) PDGFRAKITKDRPDE3APDGFRB
SCHEMBL4970154 0.87 PDGFRB (0.69) PDGFRAKITKDRPDGFRB
SCHEMBL4970207 0.87 PDGFRB (0.67) PDGFRAKITKDRPDGFRB
SCHEMBL4966363 0.87 PDGFRA (0.56) PDGFRAKITKDRPDE3APDE10A
SCHEMBL4967719 0.87 PDGFRB (0.65) PDGFRAKITKDRPDE3BPDE3A
SCHEMBL4967916 0.86 PDGFRA (0.57) PDGFRAKITKDRPDE3APDE10A
SCHEMBL4965967 0.86 PDE3B (0.64) PDE3BPDE3APDE10APDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101242838-A Synergistic modulation of FLT3 kinase using aminoquinoline and aminoquinazoline kinase modulators JANSSEN PHARMACEUTICA NV (BE) 2008-08-13 CN disclosed
EP-1899319-A2 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-19 EP disclosed
EP-1893206-A2 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-05 EP disclosed
US-20070004763-A1 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-01-04 US disclosed
US-20070004763-A1 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-01-04 US disclosed
US-20070004763-A1 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-01-04 US disclosed
WO-2006135649-A2 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-21 WO disclosed
WO-2006135636-A2 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-21 WO disclosed
US-20060281771-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281771-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS FLT3, CDC42BPG, PRKCQ PDGFRA 460/4885KIT 197/4885KDR 483/4885
US-20070004763-A1 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS FLT3, BMX, ABL1 PDGFRA 74/4885KIT 104/4885KDR 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.